Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme class drugs

4 results

  • aldurazyme

    (laronidase)
    Genzyme Corporation
    ALDURAZYME® is indicated for treating adults and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), as well as those with moderate to severe symptoms of the Scheie form. Its safety for mildly affected Scheie patients and CNS effects are not established.

  • elaprase

    (idursulfase)
    Takeda Pharmaceuticals America, Inc.
    ELAPRASE is indicated for treating Hunter syndrome (MPS II) in patients 5 years and older, improving walking capacity. In patients aged 16 months to 5 years, it reduces spleen volume, but its effects on disease symptoms are unclear. Safety and efficacy for those under 16 months remain unestablished.

  • naglazyme

    (galsulfase)
    BioMarin Pharmaceutical Inc.
    NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) and has demonstrated effectiveness in improving walking and stair-climbing capacity.

  • vimizim

    (elosulfase alfa)
    BioMarin Pharmaceutical Inc.
    Vimizim (elosulfase alfa) is indicated for the treatment of Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.